Collegium Announces the Launch of OpioidIQ
OpioidIQ provides physicians and other allied healthcare providers with tools to assess which patients are appropriate for opioid analgesics and important topics that need to be addressed with patients when deciding to treat them with an opioid analgesic, including:
- Appropriate opioid use
- Risks of unintentional misuse and abuse
- Enhancing communications between patients and healthcare providers
- Resources for providing information to patients and caregivers to avoid unintentional opioid misuse
- Role of abuse-deterrent formulations (ADFs)
“Up to 1 in 4 patients misuse their opioid medication, and many of those patients are doing so unintentionally1” said
“Opioids should only be prescribed after alternative non-opioid treatment options have been fully explored. Once a clinician has decided to prescribe an opioid to a patient, the clinician then needs to make it a point to ask the patient how he/she is taking his/her medicines. For example, are they ever crushing, chewing, or dissolving them prior to taking them,” said Dr.
For more information, visit www.OpioidIQ.com.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our products and product candidates; the existence of any patent infringement or similar litigation relating to any of our products or product candidates, and costs and delays associated with such litigation; the size and growth potential of the markets for our product and product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product and product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended
1 Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576.
Contact:Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com